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Abstract
We report a case of severe hyperparathyroidism complicated by osteitis ﬁbrosa cystica in an 83-year-old man post-
myocardial infarction. The lesions were evident on magnetic resonance imaging only. A diagnosis of parathyroid carcinoma
was considered due to clinical appearance of the parathyroid intraoperatively and the presence of an invasive T3 lesion
mimicking metastatic disease. Differentiating parathyroid carcinoma from the benign causes at presentation can be difﬁcult
due to overlapping clinical, biochemical, radiological and histological features. The presence of bony lesions increases the
diagnostic complexity of the case and demonstrates the challenges involved in the management of this disorder.
INTRODUCTION
Primary hyperparathyroidism (pHPT) is a common endocrine
disorder, with a prevalence of 0.1–0.3%. Sporadic solitary aden-
oma accounts for up to 85% of cases with 10–15% due to multi-
glandular disease. Parathyroid carcinoma accounts for less
than 1% [1]. Differentiating carcinoma from benign causes can
be difﬁcult due to overlapping clinical, biochemical, radiological
and histological features. The presence of bony lesions
increases the diagnostic complexity and demonstrates the
challenges involved in management of this disorder.
CASE REPORT
An 83-year-old man presented with incidental severe hypercalcae-
mia (Ca2+ 3mmol/l, reference 2.10–2.55) and hyperparathyroidism
(PTH 124.2 pmol/l, reference 1.5–7.6) after a myocardial infarction
complicated by cardiac failure. Thirst was his only symptom of
hypercalcaemia and may have been related to loop diuretics ther-
apy. There was no history of thiazide diuretic or lithium exposure.
He did not have any clinically evident neurological deﬁcits. He
had mild vitamin D insufﬁciency (48 nmol/l) and acute renal
impairment (eGFR 27ml/min). Past history included hypertension,
stage 3 CKD, schizophrenia, ischaemic cardiomyopathy with a
poor ejection fraction (25%) and diastolic dysfunction.
Treatment of hypercalcaemia with intravenous ﬂuids was
hampered by poor cardiac function. Cinacalcet slowly titrated
up to 60mg bi-daily adequately controlled his serum calcium at
<3mmol/l without intravenous ﬂuids.
After failed localization with sestamibi scan and ultrasound,
an magnetic resonance imaging (MRI) (Fig. 1) showed enlarged
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inferior parathyroid glands bilaterally (left 7.6 × 12 × 17mm,
right 16 × 14 × 15mm) and a T3 bony lesion (Fig. 2) not evident
on a full body bone scan. Screening for prostate cancer and
myeloma was negative.
He was originally consented for bilateral parathyroid explor-
ation. However, at neck exploration, the left parathyroid was
adherent to the oesophageal adventitia. As the surgical team
believed they were dealing with a parathyroid malignancy, a
left inferior parathyroidectomy, left hemithyroidectomy and
partial resection of the left recurrent laryngeal nerve were per-
formed with the enlarged right parathyroid gland left in situ.
The left parathyroid lesion weighed 2.06 g. Histopathology
showed features suspicious but not diagnostic of parathyroid
carcinoma (Fig. 3). There were some atypical features, including
partial nodularity with ﬁbrovascular septa surrounding tumour
nodules. Deﬁnite malignant features, namely vascular inva-
sion, perineural invasion or inﬁltration of adjacent tissues were
not identiﬁed. Paraﬁbromin and PGP9.5 immunohistochemistry
were inconclusive for HRPT2/CDC73 mutations.
Staging computed tomography (CT) showed a lytic lesion with
local invasion into the spinal canal (Fig. 4). Fludeoxyglucose
positron emission tomography (FDG-PET) demonstrated a destruc-
tive hypermetabolic soft tissue bony lesion within the T3 vertebral
body, with probable nerve root compression (Fig. 4). A right T3
hemilaminectomy was undertaken for excisional biopsy of a pre-
sumed metastasis. Histopathology showed a giant cell rich lesion,
with bone extensively replaced by mononuclear spindle cells with
scattered multinucleate giant cells, a vascular stroma, and haemo-
siderin deposition - consistent with a brown tumour (Fig. 5).
Hypercalcaemia (Ca2+ 2.6–2.96mmol/l) and hyperparathyroidism
(109.4pmol/l) persisted post-operatively. At a second neck explor-
ation a month later, a right parathyroidectomy was performed. The
lesion weighing 2.19g showed no atypical histological features con-
sistent with parathyroid adenoma or glandular hyperplasia.
Calcium and PTH levels normalized immediately and he sub-
sequently developed permanent mild hypocalcaemia requiring
calcium and calcitriol supplements.
DISCUSSION
pHPT is mostly asymptomatic in developed countries, due
to early detection from biochemical testing [2]. In severe and
Figure 1: MRI showed two non-speciﬁc soft tissue structures deep to the thyroid on both sides of the oesophagus, suspicious for enlarged parathyroid glands.
Figure 2: MRI showed a low T1 low T2 lesion in the right posterior vertebral body, pedicle, lamina and spinous process of T3.
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symptomatic cases, parathyroidectomy is the mainstay of
treatment. In patients who either refuse or have contraindica-
tions for parathyroidectomy and those with intractable disease
post-surgery, cinacalcet has been shown to effectively lower ser-
um calcium and PTH levels. It may be useful as a bridging ther-
apy in patients who have progressive hypercalcaemia awaiting
for parathyroidectomy [3].
The commonest causes of persistent and recurrent hyperpara-
thyroidism post-parathyroidectomy are multiglandular disease
and ectopic parathyroid glands. Among benign parathyroid
tumours, double adenoma have the highest recurrence rate
(up to 7%) compared to solitary adenoma and hyperplasia [4].
Four gland exploration is indicated if localization studies are
inconclusive.
Figure 3: First parathyroid lesion (left inferior parathyroid gland) showing atypical features—focal extension into the capsule (left), nodules of tumour cells sur-
rounded by thickened ﬁbrous septa (right). Deﬁnite malignant features such as vascular/perineural invasion or inﬁltration of adjacent tissues were not identiﬁed.
Left, H&E (×1.25); Right, H&E (×20).
Figure 4: Staging CT showed a lytic lesion (b bottom image) with some local invasion into the spinal canal. FDG PET scan (a and b top image) demonstrated a destruc-
tive hypermetabolic soft tissue bony lesion within the T3 vertebral body, with probable compression of the right exiting nerve root.
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The presence of the bony lesion raised the possibility of a
parathyroid carcinoma metastasis with a differential diagnosis of
primary bone tumour, metastasis with co-existing hyperparathyr-
oidism or brown tumour arising from severe hyperparathyroidism.
Multiple myeloma and metastases from renal cell carcinoma,
melanoma, thyroid, bladder, lung and breast cancers usually
appear osteolytic or mixed lytic/blastic on imaging, whereas
bony metastases from prostate cancer are predominantly
osteoblastic [5].
Parathyroid carcinoma is associated with high morbidity and
mortality. Imaging and ﬁne needle aspiration is not helpful in
differentiating parathyroid carcinoma from other benign causes
preoperatively [2]. There have been no reports of bilateral multi-
glandular parathyroid carcinoma, however, bilaterality alone
cannot be used to exclude malignancy. The histological features
of parathyroid carcinoma and atypical adenoma overlap, as do
the features of simple adenoma and parathyroid hyperplasia.
Serum calcium, PTH levels and weight of resected tumours were
signiﬁcantly greater in parathyroid carcinomas compared to
adenomas [6]. Mutations in the HRPT2/CDC73 gene, resulting in
loss of immunohistochemical staining for its protein product
paraﬁbromin are seen more frequently in parathyroid carcin-
omas than in typical adenomas. Although non-speciﬁc, it may
be used to help predict clinical outcomes [1].
As 90% of carcinomas are hormonally functional [2], patients
are more likely to present with symptoms including severe hyper-
calcaemia, pathological fractures or rarely, bony pain from brown
tumour [2]. Brown tumour (osteitis ﬁbrosa cystica) occurs in <5%
of patients with pHPT in developed countries [7]. It also occurs in
secondary and tertiary hyperparathyroidism particularly among
dialysis patients, particularly with PTH > 50pmol/l [8]. It is a
benign, non-neoplastic tumour characterized by subperiosteal
bone resorption and osteopenia [9]. It may arise in any bone, but
appears to have a craniofacial predilection. Lesions can be single
or multiple, and may be locally aggressive resembling primary
bone tumours or bony metastases [10]. The role of ﬁne needle
aspiration in differentiating these and other tumours is contro-
versial [9].
Radiologically, brown tumours appear attenuated on CT
because of hemosiderin deposition and ﬁbrous tissue in the
lesion. Similar to other benign tumours such as giant cell tumour
or aneurysmal bony cyst, brown tumours appear osteolytic on
imaging. A wide spectrum of MRI ﬁndings has been reported,
including solid, cystic or mixed lesions and different intensities
on T1- and T2-weighted images [10]. Surgical removal of brown
tumour lesions is traditionally unnecessary, as these lesions gen-
erally resolve spontaneously once hyperparathyroidism is cor-
rected [7]. Rarely, surgical intervention might be necessary in the
case of late bone recovery or in the presence of pathological frac-
tures or compressive symptoms [10].
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Figure 5: Brown tumour (within T3 vertebral body), showing a giant cell rich lesion, with bone extensively replaced by a proliferation of mononuclear spindle cells
with scattered multinucleate giant cells. These are set in a vascular stroma with some haemosiderin deposition. Upper left, H&E (×1.25); Lower left—A, H&E (×10);
Upper right—B, H&E (×20).
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